Keybanc analyst Matthew Mishan maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and raises the price target from $47 to $48.
Xylem Q4 Adj. EPS $0.92 Beats $0.79 Estimate, Sales $1.51B Beat $1.41B Estimate
Xylem (NYSE:XYL) reported quarterly earnings of $0.92 per share which beat the analyst consensus estimate of $0.79 by 16.46 percent. This is a 46.03 percent increase over earnings of $0.63 per share from the same period
